TABLE 1.

Baseline Characteristics for 134 Subjects Currently on Infliximab (n = 134) and 18 Subjects Previously on Infliximab (n = 18) Who Had Discontinued the Drug Secondary to Loss of Response, Infusion Reaction, or Lack of Initial Response

Characteristic	Current Infliximab		P
	Yes (n = 134)	No (n = 18)
	Statistic	Statistic
Age, yr	17.3 ± 4.3	17.5 ± 2.9	0.85
Male sex	85 (63%)	11 (61%)	0.85
Diagnosis			0.45
UC	20 (15%)	3 (17%)
CD	114 (85%)	15 (83%)
Disease severity
CD (PCDAI)	5 (0–10)	10 (0–25)	0.03
UC (PUCAI)	7.5 (0–15)	10 (10–30)	0.25
Disease remission
CD (PCDAI 0–10)	95 (83%)	10 (67%)	0.15
UC (PUCAI 0–9)	10 (50%)	0 (0%)	0.23
Paris classification at diagnosis
CD
Age			0.05
0–10, yr	31 (27%)	9 (60%)
10–17, yr	79 (69%)	6 (40%)
17–40, yr	4 (4%)	0 (0%)
Location
L1	15 (13%)	0 (0%)	0.21
L2	11 (10%)	2 (13%)	0.65
L3	85 (75%)	13 (87%)	0.52
L4	3 (3%)	0 (0%)	1.00
L4a	70 (61%)	12 (80%)	0.16
L4b	8 (7%)	0 (0%)	0.60
Behavior
B1	104 (91%)	14 (93%)	1.00
B2	9 (8%)	1 (7%)	1.00
B3	3 (3%)	0 (0%)	1.00
B4	42 (37%)	4 (27%)	0.44
Growth			0.50
G0	92 (81%)	11 (73%)
G1	22 (19%)	4 (27%)
UC
Location			0.44
E1	1 (7%)	0 (0%)
E2	1 (7%)	1 (33%)
E3	0 (0%)	0 (0%)
E4	13 (86%)	2 (67%)
Severity			0.17
S0	12 (80%)	1 (33%)
S1	3 (20%)	2 (67%)
Months on infliximab	24 (13–51)	15 (6–46)a	0.12
Combination therapya	50 (37%)	0 (0%)
Immunomodulators since diagnosis	119 (92%)	18 (100%)	0.36
CRP obtained	132 (99%)	17 (94%)	0.32
CRP	0.10 (0.10–0.27)	0.12 (0.10–1.26)	0.09
CRP >0.5	16 (12%)	6 (35%)	0.02
ATI ≥5	27 (20%)	4 (22%)	0.76
ATI ≥10	18 (13%)	2 (11%)	1.00
ATI ≥12	14 (10%)	2 (11%)	1.00
ATI ≥15	13 (10%)	1 (6%)	1.00

^aMedian and percentage of subjects or median and IQR are shown.

Infliximab with methotrexate or 6-mercaptopurine at the time of serum sampling.